180 related articles for article (PubMed ID: 15542783)
1. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
Janssen S; Jakobsen CM; Rosen DM; Ricklis RM; Reineke U; Christensen SB; Lilja H; Denmeade SR
Mol Cancer Ther; 2004 Nov; 3(11):1439-50. PubMed ID: 15542783
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
Janssen S; Rosen DM; Ricklis RM; Dionne CA; Lilja H; Christensen SB; Isaacs JT; Denmeade SR
Prostate; 2006 Mar; 66(4):358-68. PubMed ID: 16302271
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
4. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells.
Jakobsen CM; Denmeade SR; Isaacs JT; Gady A; Olsen CE; Christensen SB
J Med Chem; 2001 Dec; 44(26):4696-703. PubMed ID: 11741487
[TBL] [Abstract][Full Text] [Related]
6. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.
Brennen WN; Rosen DM; Wang H; Isaacs JT; Denmeade SR
J Natl Cancer Inst; 2012 Sep; 104(17):1320-34. PubMed ID: 22911669
[TBL] [Abstract][Full Text] [Related]
7. Novel peptide inhibitors of human kallikrein 2.
Hekim C; Leinonen J; Närvänen A; Koistinen H; Zhu L; Koivunen E; Väisänen V; Stenman UH
J Biol Chem; 2006 May; 281(18):12555-60. PubMed ID: 16527822
[TBL] [Abstract][Full Text] [Related]
8. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
Denmeade SR; Lövgren J; Khan SR; Lilja H; Isaacs JT
Prostate; 2001 Jul; 48(2):122-6. PubMed ID: 11433422
[TBL] [Abstract][Full Text] [Related]
9. Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology.
Cloutier SM; Chagas JR; Mach JP; Gygi CM; Leisinger HJ; Deperthes D
Eur J Biochem; 2002 Jun; 269(11):2747-54. PubMed ID: 12047384
[TBL] [Abstract][Full Text] [Related]
10. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors.
Mikolajczyk SD; Millar LS; Kumar A; Saedi MS
Prostate; 1998 Jan; 34(1):44-50. PubMed ID: 9428387
[TBL] [Abstract][Full Text] [Related]
11. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells.
Christensen SB; Skytte DM; Denmeade SR; Dionne C; Møller JV; Nissen P; Isaacs JT
Anticancer Agents Med Chem; 2009 Mar; 9(3):276-94. PubMed ID: 19275521
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors.
Lövgren J; Airas K; Lilja H
Eur J Biochem; 1999 Jun; 262(3):781-9. PubMed ID: 10411640
[TBL] [Abstract][Full Text] [Related]
13. Targeting thapsigargin towards tumors.
Doan NT; Paulsen ES; Sehgal P; Møller JV; Nissen P; Denmeade SR; Isaacs JT; Dionne CA; Christensen SB
Steroids; 2015 May; 97():2-7. PubMed ID: 25065587
[TBL] [Abstract][Full Text] [Related]
14. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.
Denmeade SR; Lou W; Lövgren J; Malm J; Lilja H; Isaacs JT
Cancer Res; 1997 Nov; 57(21):4924-30. PubMed ID: 9354459
[TBL] [Abstract][Full Text] [Related]
15. Effects of secondary interactions on the kinetics of peptide and peptide ester hydrolysis by tissue kallikrein and trypsin.
Fiedler F
Eur J Biochem; 1987 Mar; 163(2):303-12. PubMed ID: 3643848
[TBL] [Abstract][Full Text] [Related]
16. Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2.
Bourgeois L; Brillard-Bourdet M; Deperthes D; Juliano MA; Juliano L; Tremblay RR; Dubé JY; Gauthier F
J Biol Chem; 1997 Nov; 272(47):29590-5. PubMed ID: 9368023
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2.
Mize GJ; Wang W; Takayama TK
Mol Cancer Res; 2008 Jun; 6(6):1043-51. PubMed ID: 18567807
[TBL] [Abstract][Full Text] [Related]
18. Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
Quynh Doan NT; Christensen SB
Curr Pharm Des; 2015; 21(38):5501-17. PubMed ID: 26429715
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug.
Baiz D; Pinder TA; Hassan S; Karpova Y; Salsbury F; Welker ME; Kulik G
J Med Chem; 2012 Sep; 55(18):8038-46. PubMed ID: 22924393
[TBL] [Abstract][Full Text] [Related]
20. Preparation of Enzyme-Activated Thapsigargin Prodrugs by Solid-Phase Synthesis.
Zimmermann T; Christensen SB; Franzyk H
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
